What is thyroid cancer? How is it treated?

  Medullary carcinoma
  Medullary thyroid carcinoma (MTC)
  Synonym
  solid carcinoma
  solid carcinoma with amyloid stroma
  solid amyloidotic carcinoma
  C-cell carcinoma
  Compact cell carcinoma
  neuroendocrine carcinoma of thyroid
  Definition
  Malignant epithelial cell tumor of C-cell origin of thyroid gland
  Etiology/Pathogenesis
  Genetic cases
  Strong genetic correlation with multiple endocrine neoplasia syndrome (MEN)
  MEN2A (Sipple): parathyroid hyperplasia (hyperparathyroidism), medullary thyroid cancer, adrenal pheochromocytoma and endocrine tumors of the pancreas
  MEN2B (Wagenmann-Froboese syndrome) includes, in addition to the above, soft tissue tumors (usually sarcomas)
  Autosomal dominant, highly aggressive and various manifestations
  Germ cell mutations (usually point mutations) occurring on 10q11.2 that result in enhanced function of the RET gene
  RET is a fusion gene containing a gene encoding a tyrosine kinase fragment (RET, Rearranged during Transfection contraction)
  ……
  RET is also associated with papillary thyroid carcinoma (chromosomal remap also known as RET/PTC)
  Familial medullary thyroid carcinoma (FMTC) is not associated with extrathyroidal disease but is still associated with RET proto-oncogene mutations in germ cells.
  Sporadic cases
  More than 2/3 of sporadic cases have somatic RET mutations
  Other genetic or epigenetic alterations are also seen
  Pathogenesis
  C-type cells of posterior parotid origin are the primary cells of the tumor
  Type C (parafollicular) cells develop embryologically from the fourth parotid/pharyngeal bursa
  They are found in the upper middle part of the thyroid lobe
  Medullary carcinoma does not originate in the thyroid headland
  Calcitonin is a peptide hormone secreted by C-type cells to maintain calcium homeostasis in the body
  In hereditary cases, C-cell hyperplasia is the precursor of medullary carcinoma
  Epidemiology
  Incidence
  Approximately 5-8% of thyroid malignancies in the United States
  Predominantly disseminated (80%), with the remainder (20%) being hereditary (familial)
  Age
  Sporadic cases: 50-60 years
  Familial cases: 30 years old
  MEN2A: late adolescence or early adulthood
  MEN2B: infancy or early childhood
  Gender.
  Sporadic cases: female > male (1.1:1)
  Location
  Upper middle thyroid lobe
  Site of C cells and/or posterior parotid body
  The thyroid headland is not affected
  Description
  Sporadic cases
  Painless, unilateral, isolated thyroid swelling
  Approximately 50% of patients have enlarged cervical lymph nodes
  Hoarseness, wheezing, upper airway obstruction, or dysphagia in about 10-15% of patients
  Hereditary/familial cases
  Thyroid/neck presentation is the same as in disseminated cases, except that patients are younger than in disseminated cases
  More than 30% of patients have diarrhea and facial flushing, which are associated with increased plasma calcitonin levels
  Multicentric or bilateral thyroid involvement
  Clinical symptoms of other non-thyroidal organs may be predominant
  Calcium disorders due to hyperparathyroidism
  excessive sweating, headache, paroxysmal hypertension, palpitations, syncope and vertigo due to pheochromocytoma
  Cushing’s syndrome caused by ACTH or pituitary adenoma peptide products produced by the tumor
  Gastrointestinal symptoms caused by peptide secretion from pancreatic endocrine tumors
  Mucosal neuromas (oral, lip, tongue and gastrointestinal tract)
  In some familial cases, can be detected before the onset of clinical symptoms
  Parathyroid, adrenal, pituitary, pancreatic, and gastrointestinal manifestations
  Incidental finding of thyroid disease during evaluation for MEN syndrome
  Laboratory tests
  Serum calcitonin levels are elevated to varying degrees
  Elevated CEA levels
  Calcium dysregulation (triggered by calcitonin and parathyroid hormone abnormalities)
  Treatment
  Treatment strategies, risks and complications
  Prophylactic thyroidectomy for patients with germ cell RET mutations (RET phenotype specific)
  Thyroidectomy at the recommended age for patients with specific RET mutations
  Thyroidectomy before 12 months for patients with codon 883, 918 and 922 mutations
  For patients with codon 611, 618, 620 and 634 mutations, thyroidectomy before 5 years of age
  For patients with other codon mutations: thyroidectomy after abnormal pentagastrin-stimulated calcitonin response
  Surgical procedures
  Total thyroidectomy
  Neck dissection
  Central zone (zone VI)
  If the central zone lymph nodes are positive or the tumor size is more than 1 cm, an ipsilateral neck dissection should be performed
  If bilateral tumors are present, bilateral radical neck dissection should be performed
  Parathyroidectomy in some hereditary cases
  Adjuvant treatment
  Chemotherapy, growth inhibitor analogues, anti-CEA radioimmunotherapy may be indicated for some patients
  Radiotherapy
  For cases with large residual masses or distant metastases, external particle beam radiation therapy is indicated.
  Additional treatment
  Radiofrequency ablation
  Molecular targeted therapy (tyrosine kinase inhibitors targeting RET kinase)
  Prognosis
  Clinical stage and genetic type dependent
  Overall 10-year survival rate 70%-80%
  Good prognosis for those cases with smaller tumors still confined to the thyroid, incidental findings, and no lymph node metastases (100%)
  Prognosis: familial non-MEN> disseminated cases>MEN2A>MEN2B
  Best prognosis for prophylactic thyroidectomy cases, worst for cases with lymph node metastasis
  Tumor stage is the most important prognostic factor (invasive extra-thyroidal and metastatic)
  Stage I: 100 % survival rate at 10 years
  Stage III: 10-year survival rate 65%-85%
  Stage IV: 10-year survival rate 20%-50%
  Younger patients (less than 45 years old) have a better prognosis than older patients
  Women have a slightly worse prognosis (this result is still controversial)
  Lymph node metastases are more common (about 50%)
  Distant metastases are rare (about 15)
  Liver, lung, bone
  Prognosis is better in patients with amyloid-rich material and more than 75% cytocalcitonin positive
  If somatic RET mutations are present, with codon 918 mutations being the most malignant
  If preoperative serum calcitonin and CEA levels are high, they can be used as a test for follow-up